Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indian Drug Makers Squeezed Between Bulk Costs, Price Controls

This article was originally published in PharmAsia News

Executive Summary

Indian drug makers are facing an obstacle in getting drugs to market by the twin impact of increasing costs for raw materials and government pricing limits. Drug makers saw a 20 percent to 100 percent increase in the bulk drugs they imported from China during the past six months. At the same time, Indian pharmas face a 10 percent cap on their ability to raise prices. The conundrum could lead some companies to stop producing several drugs, in turn causing a shortage of those drugs on the market. Pharma industry estimates put the cost of raw materials at up to 60 percent of manufacturing costs. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts